drugset / Trial / NCT00002656
Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer
Phase 2
Completed
20 enrolled
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with pyrazoloacridine in treating patients with stage IIIB or stage IV non-small cell lung cancer.
Timeline
- Start
- 1995-10
- Primary completion
- 2001-12
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | pyrazoloacridine | Small molecule | 600 mg/m2 | Intravenous |
| Subject | pyrazoloacridine | Small molecule | 750 mg/m2 | Intravenous |
| Subject | pyrazoloacridine | Small molecule | 820 mg/m2 | Intravenous |